

Livers with risk factors for HCC, Cirrhosis and Chronic Hep B
Arterial enhancement (non-rim)
October 2026
No
Yes
<20mm
≥20mm
<10mm
10-19mm
≥20mm
Major features
Major features
Major features
Major features
Major features
≤1
≥2
None
≥1
No
Yes
No
Enhancing capsule only
Washout or growth
No
Any
LR3
LR4
LR3
36% Intermediate
LR4
72% Probably HCC
LR5
96% Definite HCC
Ancillary Features for HCC
Major Features;
Non-peripheral washout
Enhancing capsule / Pseudocapsule
Threshold growth ≥ 50% in ≤ 6 months
Ancillary Features favouring HCC;
Nodule-in-nodule
Mosaic architecture
Blood products
Fat content
Repeat in 3 months. No MDT discussion
If stable over 3 months, then 6 monthly follow up
Cease F/U if stable over 24 months
Local MDT
For tailored work up- may include biopsy
Local and Network MDT
Copyright P Carruthers Radiology Services